Clearline Capital LP Coherus Bio Sciences, Inc. Call Options Transaction History

Clearline Capital LP

  • $2 Billion
  • Q3 2025

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

About Coherus BioSciences, Inc.

CHRS Quotes by TradingView
  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $92.5M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Clearline Capital LP Portfolio

Follow Clearline Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Clearline Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Clearline Capital LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email